利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.036 秒)

    Method for producing hematopoietic stem cells using pyrazole compounds
    6.
    发明授权
    Method for producing hematopoietic stem cells using pyrazole compounds 有权
    使用吡唑化合物制造造血干细胞的方法

    公开(公告)号：US09212348B2

    公开(公告)日：2015-12-15

    申请号：US13990959

    申请日：2011-12-01

    申请人： Taito Nishino ,  Makiko Yui ,  Yasuyuki Asai ,  Ayako Asai

    发明人： Taito Nishino ,  Makiko Yui ,  Yasuyuki Asai

    IPC分类号： C12N15/00 ,  C12N5/0789 ,  C07D231/22 ,  A61K35/28

    CPC分类号： C12N5/0647 ,  A61K35/28 ,  C07D231/22 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/26 ,  C12N2501/999

    摘要： An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided.A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R8 are as defined in the description).

    摘要翻译： 提供了用作造血干细胞和/或造血祖细胞的扩增剂，其用作各种造血疾病的治疗，并且可用于提高基因转移到造血干细胞中用于基因治疗的效率。 一种产生造血干细胞和/或造血祖细胞的方法，其包括通过在下列通式（I）表示的化合物存在下体外培养造血干细胞来扩大造血干细胞，其中所述化合物的互变异构体或药学上可接受的盐 化合物或其溶剂化物（其中R1至R8如说明书中所定义）。

    Pyrazole compounds having therapeutic effect on multiple myeloma
    7.
    发明授权
    Pyrazole compounds having therapeutic effect on multiple myeloma 有权
    对多发性骨髓瘤具有治疗作用的吡唑类化合物

    公开(公告)号：US08658686B2

    公开(公告)日：2014-02-25

    申请号：US13991024

    申请日：2011-12-01

    申请人： Taito Nishino ,  Katsuaki Miyaji ,  Shunsuke Iwamoto ,  Takumi Mikashima ,  Koichiro Saruhashi ,  Yo Kishikawa

    发明人： Taito Nishino ,  Katsuaki Miyaji ,  Shunsuke Iwamoto ,  Takumi Mikashima ,  Koichiro Saruhashi ,  Yo Kishikawa

    IPC分类号： A61K31/415 ,  C07D231/10

    CPC分类号： C07D231/20 ,  C07D401/06 ,  C07D403/06

    摘要： Novel therapeutic agents for myeloma are provided.A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R1 is C1-C6 alkyl, C1-C6 alkyl substituted with R17, C1-C6 haloalkyl, phenyl, phenyl substituted with a R11's or the like, R2 is a hydrogen atom, C1-C6 alkyl, phenyl or phenyl optionally substituted with e R21's or the like, R3 is a hydrogen atom or the like, X is a single bond or —(CR6R7)n—, each of R4 and R5 is independently C1-C6 alkyl or the like, R6 and R7 are hydrogen atoms or C1-C6 alkyl, R8 is phenyl, phenyl optionally substituted with k R81's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

    摘要翻译： 提供了新型骨髓瘤治疗剂。 一种含有由式（1）表示的吡唑化合物的多发性骨髓瘤治疗剂：其中R1是C1-C6烷基，被R17取代的C1-C6烷基，C1-C6卤代烷基，苯基，被R11等取代的苯基， R 2是氢原子，C 1 -C 6烷基，苯基或任选被e R 21等取代的苯基，R 3是氢原子等，X是单键或 - （CR 6 R 7）n - 各自为R 4和R 5 独立地为C 1 -C 6烷基等，R 6和R 7为氢原子或C 1 -C 6烷基，R 8为苯基，任选被k R 81等取代的苯基，化合物的互变异构体或其药学上可接受的盐或溶剂合物， 作为活性成分。

    Thrombopoetin receptor activator and process for producing the same
    8.
    发明授权
    Thrombopoetin receptor activator and process for producing the same 失效
    血小板生成素受体激活剂及其制备方法

    公开(公告)号：US07851503B2

    公开(公告)日：2010-12-14

    申请号：US10524666

    申请日：2003-08-14

    申请人： Katsuaki Miyaji ,  Norihisa Ishiwata ,  Takanori Nakamura ,  Taito Nishino ,  Hisao Kamiya ,  Masao Yamamoto

    发明人： Katsuaki Miyaji ,  Norihisa Ishiwata ,  Takanori Nakamura ,  Taito Nishino ,  Hisao Kamiya ,  Masao Yamamoto

    IPC分类号： A61K31/275

    CPC分类号： A61K31/4409 ,  A61K31/277 ,  A61K31/4402 ,  A61K31/4453 ,  C07C255/37

    摘要： A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): [wherein each of R1 and R3 is independently a hydrogen atom, SO3H, a C1-6 alkyl group, a C1-6 alkylcarbonyl group or a C6-18 arylcarbonyl group (the C1-6 alkyl group, the C1-6 alkylcarbonyl group and the C6-18 arylcarbonyl group may be optionally substituted with a halogen atom, a hydroxyl group, a C2-6 alkenyl group, a C1-6 alkoxy group, a C1-6 alkoxycarbonyl group, a C6-18 aryl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-furanyl group, a 3-furanyl group, a 2-thienyl group, a 3-thienyl group or NR9R10) , and each of R2, R4 and Ra is independently a hydrogen atom, a hydroxyl group or a C1-6 alkoxy group].

    摘要翻译： 含有血小板生成素受体活化剂的式（1）表示的血小板生成素受体活化有效的疾病或血小板增多剂的预防，治疗或改善剂：其中R 1和R 3各自独立地为氢原子 ，SO 3 H，C 1-6烷基，C 1-6烷基羰基或C 6-18芳基羰基（C 1-6烷基，C 1-6烷基羰基和C 6-18芳基羰基可以任选地被 卤素原子，羟基，C 2-6烯基，C 1-6烷氧基，C 1-6烷氧基羰基，C 6-18芳基，2-吡啶基，3-吡啶基， 吡啶基，2-呋喃基，3-呋喃基，2-噻吩基，3-噻吩基或NR9R10），R2，R4和Ra各自独立地为氢原子，羟基或C1 -6烷氧基]。